New 'nanoburrs' could add to arsenal of therapies against heart disease

Jan 18, 2010 by Anne Trafton

(PhysOrg.com) -- Researchers at MIT and Harvard Medical School have built targeted nanoparticles that can cling to artery walls and slowly release medicine, an advance that potentially provides an alternative to drug-releasing stents in some patients with cardiovascular disease.

Building on their previous work delivering cancer drugs with nanoparticles, MIT and Harvard researchers have turned their attention to cardiovascular disease, designing new particles that can cling to damaged artery walls and slowly release medicine.

The particles, dubbed “nanoburrs,” are coated with tiny protein fragments that allow them to stick to damaged arterial walls. Once stuck, they can release drugs such paclitaxel, which inhibits cell division and helps prevent growth of scar tissue that can clog arteries.

“This is a very exciting example of nanotechnology and cell targeting in action that I hope will have broad ramifications,” says MIT Institute Professor Langer, senior author of a paper describing the nanoparticles in this week’s issue of the Proceedings of the National Academy of Sciences.

Langer and Omid Farokhzad, associate professor at Harvard Medical School and another senior author of the paper, have previously developed nanoparticles that seek out and destroy tumors. Their nanoburrs, however, are among the first particles that can zero in on damaged vascular tissue.

Mark Davis, professor of chemical engineering at Caltech, says the work is a promising step towards new treatments for cardiovascular and other diseases. “If they could do this in patients — target particles to injured areas — that could open up all kinds of new opportunities,” says Davis, who was not involved in this research.

On target

Currently, one of the standard ways to treat clogged and damaged arteries is by implanting a vascular stent, which holds the artery open and releases drugs such as paclitaxel. The researchers hope that their new nanoburrs could be used alongside such stents — or in lieu of them — to treat damage located in areas not well suited to stents, such as near a fork in the artery.

The nanoburrs are targeted to a structure known as the basement membrane, which lines the arterial walls but is only exposed when those walls are damaged. To build their nanoparticles, the team screened a library of short peptide sequences to find one that binds most effectively to molecules on the surface of the basement membrane. They used the most successful, a seven-amino-acid sequence called C11, to coat the outer layer of their nanoparticles.

The inner core of the 60-nanometer-diameter particles carries the drug, which is bound to a polymer chain called PLA. A middle layer of soybean lecithin, a fatty material, lies between the core and the outer shell, which consists of a polymer called PEG that protects the particles as they travel through the bloodstream.

The drug can only be released when it detaches from the PLA polymer chain, which occurs gradually by a reaction called ester hydrolysis. The longer the polymer chain, the longer this process takes, so the researchers can control the timing of the drug’s release by altering the chain length. So far, they have achieved drug release over 12 days, in tests in cultured cells.

Uday Kompella, professor of pharmaceutical sciences at the University of Colorado, says the nanoburr’s structure could make it easier to manufacture, because the targeted peptides are attached to an outer shell and not directly to the drug-carrying core, which would require a more complicated chemical reaction. The design also reduces the risk of the nanoparticles bursting and releasing drugs prematurely, says Kompella, who was not involved in this research.

Another advantage of the nanoburrs is that they can be injected intravenously at a site distant from the damaged tissue. In tests in rats, the researchers showed that nanoburrs injected near the tail are able to reach their intended target — walls of the injured carotid artery but not normal carotid artery. The burrs bound to the damaged walls at twice the rate of nontargeted nanoparticles.

Because the particles can deliver drugs over a longer period of time, and can be injected intravenously, patients would not have to endure repeated and surgically invasive injections directly into the area that requires treatment, says Juliana Chan, a graduate student in Langer’s lab and lead author of the paper.

The team is now testing the nanoburrs in rats over a two-week period to determine the most effective dose for treating damaged vascular tissue. The particles may also prove useful in delivering drugs to tumors.

 “This technology could have broad applications across other important diseases, including cancer and inflammatory diseases where vascular permeability or vascular damage is commonly observed," says Farokhzad.

Explore further: Gold nanoparticles help target, quantify breast cancer gene segments in a living cell

More information: "Spatiotemporal controlled delivery of nanoparticles to injured vasculature," Juliana Chan, Liangfang Zhang, Rong Tong, Debuyati Ghosh, Weiwei Gao, Grace Liao, Kai Yuet, David Gray, June-Wha Rhee, Jianjun Cheng, Gershon Golomb, Peter Libby, Robert Langer, Omid Farokhzad. Proceedings of the National Academy of Sciences, week of Jan. 18, 2010.

Related Stories

Targeted Nanoparticles Destroy Prostate Tumors

Apr 25, 2006

Biodegradable polymer nanoparticles, linked to a protein-binding nucleic acid known as an aptamer and loaded with the anticancer agent docetaxel, can target and kill prostate tumors growing in mice. Using this targeted nanoparticle ...

Gold nanoparticles for controlled drug delivery

Dec 30, 2008

(PhysOrg.com) -- Using tiny gold particles and infrared light, MIT researchers have developed a drug-delivery system that allows multiple drugs to be released in a controlled fashion.

New Nanoparticles for Targeting Tumors

Mar 27, 2008

As a wide variety of nanoparticles continue to demonstrate their ability to improve the delivery of imaging agents and drugs to tumors, nanoparticle researchers have turned their attention to the challenge of systematically ...

Regulated drug release thanks to nano bubbles

May 30, 2007

Stents are medical implants that, for example, prevent the blocking of arteries after surgery. One of the problems using stents is the biocompatibility as the human body rejects and attacks foreign material. ...

Stealth particles to target tumors

Aug 31, 2005

Stealth nano particles may some day target tumor cells and deliver medication to specific body locations, according to Penn State chemical engineers.

New computer model could lead to safer stents

Dec 02, 2009

(PhysOrg.com) -- After suffering heart attacks, patients often receive stents designed to hold their arteries open. Some of these stents release drugs that are meant to halt tissue growth in arteries, but ...

Recommended for you

Cloaked DNA nanodevices survive pilot mission

Apr 22, 2014

It's a familiar trope in science fiction: In enemy territory, activate your cloaking device. And real-world viruses use similar tactics to make themselves invisible to the immune system. Now scientists at ...

Innovative strategy to facilitate organ repair

Apr 18, 2014

A significant breakthrough could revolutionize surgical practice and regenerative medicine. A team led by Ludwik Leibler from the Laboratoire Matière Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ...

User comments : 0

More news stories

Research proves nanobubbles are superstable

The intense research interest in surface nanobubbles arises from their potential applications in microfluidics and the scientific challenge for controlling their fundamental physical properties. One of the ...